Merck & Co., Inc. $MRK Shares Sold by Convergence Financial LLC

Key Points

• Convergence Financial LLC cut its Merck stake by 44.5% in the third quarter, selling 8,693 shares and retaining 10,863 shares valued at approximately $1.58 million. Institutional investors collectively own 76.07% of MRK.
• Merck’s oncology pipeline remains a key growth driver: KEYTRUDA reduced progression or death risk by 43% in a Phase 3 endometrial-cancer trial, while the Moderna-partnered melanoma vaccine cut recurrence risk by 42%.
• Investors face mixed near-term signals ahead of earnings, including strong KEYTRUDA demand and mostly favorable analyst ratings, offset by weaker Gardasil demand, difficult comparisons, declining estimates and patent concerns. Analysts give MRK a consensus “Moderate Buy” rating with an average $153.12 price target.

Convergence Financial LLC lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 44.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,863 shares of the company's stock after selling 8,693 shares during the period. Convergence Financial LLC's holdings in Merck & Co., Inc. were worth $1,579,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. lifted its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares during the period. State Street Corp grew its holdings in Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock worth $15,573,754,000 after purchasing an additional 1,087,583 shares during the period. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Bank of America Corp DE grew its holdings in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock valued at $1,858,938,000 after purchasing an additional 2,969,856 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s KEYTRUDA reduced the risk of disease progression or death by 43% in a Phase 3 endometrial-cancer trial. The result strengthens the company’s oncology franchise and could support future label expansion and revenue growth. Merck's KEYTRUDA Cuts Progression Risk By 43% In Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Additional oncology readouts, including positive results from the Moderna-partnered melanoma vaccine and other cancer treatments, are providing fresh support for Merck’s pipeline and long-term growth prospects. Merck Gains Fresh Oncology Backing As Valuation Debate Heats Up
• Positive Sentiment: Broker commentary remains broadly constructive, with Barclays forecasting significant appreciation potential and other analysts highlighting KEYTRUDA demand and new-drug growth ahead of the earnings release. Barclays Forecasts Strong Price Appreciation for Merck
• Neutral Sentiment: Merck is scheduled to report third-quarter results before the market opens on October 29. Investors are focused on KEYTRUDA sales, full-year guidance and management’s outlook for the pipeline. Dear Merck Stock Fans, Mark Your Calendars for October 29
• Neutral Sentiment: The Moderna-Merck melanoma vaccine cut recurrence risk by 42% in a Phase 3 trial, but the outcome reportedly fell short of investor expectations, limiting its immediate effect on MRK. Merck and Moderna's Cancer Vaccine Worked
• Negative Sentiment: Pre-earnings concerns include difficult year-over-year comparisons, declining earnings estimates, weaker Gardasil demand and looming patent exposure. These factors could offset strong KEYTRUDA performance and increase volatility around the report. Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $141.03 on Thursday. The stock has a market cap of $347.95 billion, a price-to-earnings ratio of 112.83, a PEG ratio of 6.74 and a beta of 0.21. The firm's 50-day moving average is $147.01 and its 200 day moving average is $126.31. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.'s revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.64 EPS for the current fiscal year.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard R. Deluca sold 20,784 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president directly owned 134,703 shares of the company's stock, valued at $17,569,312.29. This trade represents a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

MRK has been the subject of several recent research reports. Zacks Research lowered shares of Merck & Co., Inc. from a "hold" rating to a "strong sell" rating in a report on Monday, October 19th. HSBC upped their price target on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Wall Street Zen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. JPMorgan Chase & Co. raised their price objective on Merck & Co., Inc. from $150.00 to $165.00 and gave the company an "overweight" rating in a research report on Monday, October 5th. Finally, Guggenheim lifted their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, September 8th. Seventeen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $153.12.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.